Document:

EX-10.19

 Exhibit 10.19 
  

 
 215 First St, Suite 200 

Cambridge, MA 02142 
 March 13, 2017 

Jigar Raythatha 
 Dear Jigar, 

It is my pleasure to offer to you the position of President & CEO at Constellation Pharmaceuticals, Inc. (“the Company”).
This letter and accompanying enclosures will summarize the terms of your employment, should you accept our offer.
 Employment: You will be
employed to serve in the position of President & CEO, reporting to the Board of Directors. In addition you will be appointed to the Company’s Board of Directors. You agree to devote your full business time, best efforts, skill,
knowledge, attention, and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company effective March 20, 2017 or such other date as mutually
agreed upon provided it is no later than April 1, 2017. 
 Compensation: Your base rate of compensation will be at the bi-weekly rate of $15,000.00 (annualized rate of $390,000), which will be paid in accordance with the Company’s regular payroll system. Such base rate of compensation may be adjusted from time to time in
accordance with normal business practices and in the sole discretion of the Company. 
 Annual Discretionary Bonus: If the Board of Directors of the
Company approves funding an annual bonus pool for the applicable fiscal year, you will be eligible for participation in the Company’s performance-based cash bonus program using the bonus benchmark of 40% of your annualized base salary as
determined by the Board of Directors in its sole discretion; provided, however, that any bonus for the 2017 calendar year shall be prorated based on your start date. The bonus award, if any, will be based on achievement of both individual and
Company performance. The Board or its designee in its sole discretion, shall determine whether to award an annual bonus and whether there has been achievement of the applicable targets. Any bonus will be paid to you following the close of the fiscal
year to which it relates and in no event later than March 15th of the calendar year in which the bonus was awarded. In any event, you must be an active employee of the Company on the date the bonus is distributed in order to be eligible for a bonus
award, as the bonus also serves as an incentive to remain employed by the Company. 
 Sign-On Bonus: You will
receive a sign-on bonus in the amount of $50,000.00, payable on the first pay date following the commencement of your employment. Should you resign without the mutual agreement of the Board of Directors or be
terminated for Cause by the Company within the first 12 months of employment, you will be required to repay the Company within 30 days following such termination an amount equal to $4,166.66 multiplied by the number of calendar months remaining
until the first anniversary of your start date with the Company. By countersigning this offer letter, you hereby agree to make any repayment required pursuant to this paragraph. 

 Special Bonus: You will also be eligible to receive a $50,000.00 special retention bonus, less applicable
taxes and withholdings. This bonus will be paid if a business deal generating at least $50,000,000 of guaranteed revenue for the Company is executed within 12 months of your start date. 

Withholdings: All compensation payable to you shall be subject to applicable taxes and withholdings. 

Stock Options: Subject to approval by the Company’s Board of Directors, you will be granted an option to purchase up to 5,900,000
shares of the Company’s common stock, at a price equal to the fair market value of the common stock on the date of the grant, as determined by the Board. This option, if granted, will be subject to the standard terms and conditions of
the Constellation Pharmaceuticals Stock Option Plan and the stock option agreement that you must execute in connection therewith. As set forth in the agreement the option will vest over four years at the rate of 25% after twelve months of
active employment and an additional 6.25% per quarter for the next twelve successive quarters when, after four full years of active employment, the option will be fully vested. Should you leave the Company before the completion of 12 months of
employment with the mutual agreement of the Board of Directors as the result of an alternative CEO being hired there will be a 2.1% accelerated vesting for each complete month you have been employed. 

Benefits: You shall also be eligible to participate in any and all other benefit programs that the Company establishes and makes available to its
employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents governing those programs, including enrollment in the Company’s 401(k) plan, which is currently being offered through
Fidelity Investments. Enclosed is a summary of the benefits, which are currently provided to the employees of Constellation Pharmaceuticals. Please note that the benefits made available by the Company, and the rules, terms, and conditions for
participation in such benefit plans, may be changed by the Company at any time, and from time to time without advance notice. 
 Change In Control:
The Company has adopted a Change in Control Severance Plan (the “Plan”). This Plan is the sole agreement between the Company and you governing any compensation and/or benefits, equity or otherwise, that you may be eligible to receive in
connection with a “Change in Control” (as defined in the Plan), including any and all benefits you may be eligible to receive if you are separated from employment on or following a Change in Control. In the event there is a conflict
between the terms of this offer letter and the terms of the Plan, the terms of the Plan shall govern. 
 Employment
At-Will: This offer letter is not intended to create or constitute an employment agreement or contract between you and Constellation for any definite period of time. If you accept the Company’s
offer of employment, your employment with the Company will be on an “at-will” basis, meaning that you will have the right to terminate your employment relationship with Constellation at any time for
any reason, with or without notice. Similarly, Constellation will have the right to terminate its employment relationship with you at any time for any reason, with or without notice.

 Severance Benefits Except in the Event of a Change in Control: Without limiting the at-will nature of your employment with the Company, in the event that Constellation terminates your employment at any time without Cause or if you resign from your employment for Good Reason, Constellation shall pay
you in one lump sum a severance payment equivalent to one (1) month’s base salary per month of employment served up to a total of 12 months of your then current base salary, less applicable taxes and withholdings. In addition, for the same
period of time provided for in the cash severance payment, or until you obtain alternative coverage, whichever comes first, and provided that you are eligible for and elect group medical and dental insurance continuation coverage pursuant to the
federal COBRA law, Constellation will continue to pay its share of the premiums associated with the COBRA continuation coverage to the same extent it was paying such premiums immediately prior to your separation date. Should your employment
termination be by mutual agreement between you and the Company, you will be ineligible for cash severance and any other benefits provided for with the exception of those benefits required for by law. 

Constellation’s obligations to make, and commence payment of, the severance and premium payments set forth in the section above are contingent upon your
execution of a Severance Agreement and Release of Claims (the “Release”) in a form to be provided by the Company (which will include, at a minimum, a release of all releasable claims and
non-disparagement, confidentiality, and cooperation obligations). The Release must be signed by you, and any applicable revocation period with respect thereto must have expired, by the 60th day following the end of your employment. If the Release has been signed by you and the Company and any applicable revocation period has expired prior to the 60th day following the end of your employment, then the severance and premium payments described above may be made or commence, as applicable, on such earlier date as may be determined by the Company;
provided, however, that if the 60th day following the end of your employment occurs in the calendar year following the year of your separation date, then the payment shall not be made
earlier than January 15 of such subsequent calendar year. 
 For the avoidance of doubt, you shall not be entitled to any severance benefits beyond
those provided for in this section by virtue of the end of your employment, except in the event a Change of Control as defined in the Plan has occurred, in which case the severance benefits provided to you as a result of the end of your employment
will be as set forth in and pursuant to the terms of the Plan and you will be entitled to no other severance benefits, including those set forth in this section. 

Cause: For purposes of this offer letter (and your eligibility to receive and retain certain benefits as set forth in this offer letter),
“Cause” shall mean (i) a material breach of any material term of any applicable offer letter or the Employee Non-Competition, Non-Solicitation,
Confidentiality and Assignment Agreement referred to below, (ii) a plea of guilty or nolo contendere to, or conviction of, the commission of a felony offense or a crime of dishonesty, (iii) repeated unexplained or unjustified absences,
refusals or failures to carry out the lawful directions of the Board of Directors of the Company (the “Board”) or the Chief Executive Officer, or the employee’s supervisor, or (iv) willful misconduct
that results or is reasonably likely to result in material harm to Constellation. 
 Good Reason: is defined as (1) a material diminution in the
Officer’s base compensation; (2) a material diminution in the Officer’s authority, duties, or responsibilities; (3) a material diminution in the authority, duties, or responsibilities of the employee to whom the Officer is
required to report, including a requirement that an Officer report to a corporate officer or employee instead of reporting directly to the Board (or similar governing body with respect to an entity other than a corporation); (4) a material
diminution in the budget over which the Officer retains authority; (5) a material change in the geographic location at which the Officer must perform the services; or (6) any other action or inaction that constitutes a material breach by
the Company of any agreement under which the Officer provides services. 

 Payments Subject to Section 409A: This offer letter, and any payments or other benefits
under this offer letter, is intended to comply, to the extent applicable, with the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and shall, to the extent practicable, be construed in
accordance with such section and consistent with Exhibit A to this offer letter. 
 Company Agreement and Employment Eligibility: The
offer of employment is contingent upon satisfactory reference checks, your signing Constellation’s standard Form of Agreement Regarding Inventions, Confidentiality and Proprietary Information (copy attached) and
I-9 Employment Verification Form. You will be required to submit documentation that establishes identity and employment eligibility in accordance with the US Immigration and Naturalization requirements
within the first three days of your employment with the Company.
 Company Policies and Procedures: As an employee of the Company, you will be
required to comply with all Company policies and procedures. Violations of the Company’s policies may lead to immediate termination of your employment. Further, the Company’s premises, including all workspaces, furniture, documents, and
other tangible materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company at any time. Company
employees should have no expectation of privacy with regard to any Company premises, materials, resources, or information. 
 Miscellaneous: You
represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with
the terms of this letter. If there are any other agreements of any type that you are aware of which may impact or limit your ability to perform your job at Constellation, please let us know as soon as possible. 

Please note that this offer letter is your formal offer of employment and supersedes any and all prior or contemporaneous agreements,
discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes under this letter will be governed by Massachusetts law. 

Please indicate your acceptance of this offer by signing on the appropriate space below and returning a signed copy either electronically or
along with the other necessary agreements referenced in this letter to the attention of Brenda Sousa at Constellation Pharmaceuticals. We will discuss a formal start date and transition plan upon your acceptance of this offer. 

We are all very excited about the opportunity to work with you, Jigar. Feel free to contact Brenda Sousa or me if you have any questions or
need more information. On behalf of all our team members, let me extend a sincere welcome. 
 Sincerely, 

	
	 /s/ Mark A. Goldsmith

	Mark A. Goldsmith, M.D., Ph.D.
	Chairman of the Board
	Constellation Pharmaceuticals, Inc.

 I accept the above terms of employment as stated: 
  

					
	 /s/ Jigar Raythatha
	 	 5/16/17            
	 	
	Jigar Raythatha	 	Date	 	

 Enclosures: 
 ~Summary of
Constellation Benefits 
 ~Constellation’s Standard Form of Agreement Regarding Employee 

   Non-Competition, Non-Solicitation, Confidentiality and
Assignment 

 Exhibit A 

Payments Subject to Section 409A 

The following rules shall apply with respect to distribution of the payments and benefits, in any, to be provided under this offer letter: 

 

	 	(a)	It is intended that each installment of the severance payments and benefits provided under this offer letter shall be treated as a separate “payment” for purposes of Section 409A of the Internal Revenue
Code and the guidance issued thereunder (“Section 409A”). Neither you nor Constellation shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required
by Section 409A. 

  

	 	(b)	If, as of the date of your “separation from service” from Constellation, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the severance payments
and benefits shall be made on the dates and terms set forth in this offer letter. 

  

	 	(c)	If, as of the date of your “separation from service” from Constellation, you are a “specified employee” (within the meaning of Section 409A), then: 

 

	 	(i)	Each installment of the severance payments and benefits due under this offer letter, that in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from
service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation
Section 1.409A-1(b)(4) to the maximum extend permissible under Section 409A and shall be made on the dates and terms set forth in this offer letter; and 

 

	 	(ii)	Each installment of the severance and benefits due under this offer letter that is not described in paragraph (i) above and that would, absent this subsection, be paid within the
six-month period following your “separation from service” from Constellation shall not be paid until the date that is six months and one day after such separation from service, (or, if earlier, upon
your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your separation
from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and
benefits if any to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
Section 1.409A-1(b)(iii) (relating to separation pay upon an involuntary “separation from service”. Any installments that qualify for the exception under Treasury Regulation Section 1.409A-
1(b)(9)(iii) must be paid no later than the last day of the Employee’s second taxable year following the taxable year in which separation from service occurs. 

	 	(d)	The determination of whether and when your separation from service from Constellation has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this paragraph (d), “Constellation” shall include all persons with whom Constellation would be considered a single employer under Sections 414(b) and 414(c)
of the Code. 

  

	 	(e)	All reimbursements and in-kind benefits provided under this offer letter shall be made or provided in accordance with the requirements of Section 409A to the extent that such
reimbursements or in-kind benefits are subject to Section 409A, including, where applicable the requirement that (i) any reimbursement is for expenses incurred during your lifetime (or during a
shorter period of time specified in this offer letter), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of
an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.

  

	 	(f)	Notwithstanding anything to the contrary in this offer letter, any payment or benefit under this offer letter or otherwise that may be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9)(v)(A) or (C) (relating to certain reimbursements and in-kind benefits) shall be paid or provided to you only to the extent that the expenses are
not incurred, or the benefits are not provided, beyond the last day of the second calendar year following the calendar year in which your “separation from service” occurs; and provided further that such expenses are reimbursed no later
than the last day of the third calendar year following the calendar year in which your “separation from service” occurs.EX-10.20

 Exhibit 10.20 
  

 
 215 First St, Suite 200 

Cambridge, MA 02142 
 August 30, 2017 

Emma Reeve 
 Dear Emma, 

It is my pleasure to confirm our offer to you for the position of Sr. Vice President & Chief Financial Officer at Constellation Pharmaceuticals, Inc.
(“the Company”). This letter and accompanying enclosures will summarize important details about your employment.
 Employment: You
will be employed to serve on a full-time basis in the position of Sr. Vice President & Chief Financial Officer, reporting to the Chief Executive Officer (“CEO”). You agree to devote your full business time, best efforts, skill,
knowledge, attention, and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company, effective on such date as is mutually agreed upon by you and
the Company (which shall in no event be later than October 16, 2017). 
 Base Salary: Your base salary will be at the rate of $13,654.00 per bi-weekly pay period (which if annualized equals $355,000), less all applicable taxes and withholdings and which will be paid in accordance with the Company’s regular payroll practices.

Annual Discretionary Bonus: Following the end of each fiscal year, and provided that the Board of Directors of the Company (the “Board”)
approves funding an annual bonus pool for such fiscal year, you will be eligible for a retention and performance bonus (the “Performance Bonus”). The target amount of such Performance Bonus will be 35% of your annualized base salary for
the applicable fiscal year, based on the Company’s achievement of its performance goals and your achievement of your performance goals for the fiscal year. The Board or its designee, in its sole discretion, shall determine whether goals have
been achieved and whether a Performance Bonus will be awarded. Any Performance Bonus will be paid to you following the close of the fiscal year to which it relates (but in no event later than March
15th). In any event, you must be an active employee of the Company on the date any Performance Bonus is distributed in order to be eligible for and to earn a bonus award, as it also serves as an
incentive to remain employed by the Company. 
 Sign on Bonus: You will receive a one-time sign-on bonus in the amount of $70,000.00, less all applicable taxes and withholdings, to be paid on the Company’s first regular pay date whose cutoff date follows your commencement of employment. Please
note that if, prior to the one-year anniversary of your start date, you resign your employment without Good Reason (as defined below) or your employment is terminated for Cause (as defined below), you will be
required to repay the Company (within thirty (30) days following your separation date) an amount equal to $5,833.33 per complete calendar month remaining between your separation date and the one-year
anniversary of your start date. On the first anniversary of your start date with the Company, you will be eligible to receive an additional bonus of $70,000 (the “Second Bonus”), less applicable taxes and withholdings. 

 Special Bonus: You will also be eligible to receive a one-time
special retention bonus of $70,000.00, less all applicable taxes and withholdings (the “Special Bonus”), if the Company has successfully completed a liquidity event by June 30, 2019. In such event, you will be paid the Special Bonus
in the Company’s next regular payroll cycle beginning after such Initiation. You must be an active employee of the Company on the date any Special Bonus is distributed in order to be eligible for and to earn such bonus. 

Withholdings: All compensation payable to you shall be subject to applicable taxes and withholdings. 

Initial Stock Option Grant: Subject to approval by the Board, you will be granted an option to purchase up to 1,600,000
shares of the Company’s common stock (the “Initial Option”), at a price equal to the fair market value of the common stock on the date of the grant, as determined by the Board. This Initial Option, if granted, will be subject
to the standard terms and conditions of the Constellation Pharmaceuticals Stock Option Plan and the stock option agreement provided in connection therewith. As set forth in the stock option agreement, the Initial Option will vest over four
years at the rate of 25% after twelve months of active employment beginning with start date and an additional 6.25% per quarter in accordance with the specific terms provided in the stock option agreement. 

Following the end of each fiscal year, and provided that the Board of Directors of the Company (the “Board”) approves employee stock option grants,
you will be eligible for a performance based option grant. The target amount of such grant is based on the Company’s achievement of its performance goals and your individual performance for the fiscal year. The Board or its designee, in its
sole discretion, shall determine whether goals have been achieved and whether an option grant will be awarded. 
 Benefits: You may participate in
any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents governing those programs, including the
Company’s 401(k) plan, which is currently being offered through Fidelity Investments. Enclosed is a summary of the benefits that are currently provided to the employees of Constellation Pharmaceuticals. Please note that the benefits made
available by the Company, and the rules, terms, and conditions for participation in such benefit plans, may be changed by the Company at any time, and from time to time without advance notice. 

Change In Control: The Company has adopted a Change in Control Severance Plan (the “Plan”), in which you are eligible to
participate and that will be provided to you under separate cover. The Plan is the sole agreement between the Company and you governing any compensation and/or benefits, equity or otherwise, that you may be eligible to receive if your employment
with the Company (or its successor in a “Change in Control” (as defined in the Plan) is terminated other than for “Cause” (as defined in the Plan) or terminates for “Good Reason” (as defined in the Plan) during the
Protected Period (as defined in the Plan), but not in the event of death or disability. In the event there is a conflict between the terms of this offer letter and the terms of the Plan, the terms of the Plan shall govern. For the avoidance of
doubt, if you are eligible for benefits under the Plan, you will not be eligible to receive the Severance Benefits (as defined below) or the Additional Severance Benefit (as defined below). The vesting under the Plan will apply to both the Initial
Option and the Performance Grant. 

 Employment At-Will: This offer letter is not intended to create or
constitute an employment agreement or contract between you and Constellation for any definite period of time and shall not be construed as an agreement, either express or implied, to employ you for any stated term. If you accept the
Company’s offer of employment, your employment with the Company will be on an “at-will” basis, meaning that both the Company and you remain free to end the employment relationship for any
reason, at any time, with or without cause or notice. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the
“at-will” nature of your employment may only be changed by a written agreement signed by you and the CEO that expressly states the intention to modify the
at-will nature of your employment. Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your
employment with the Company, except as otherwise explicitly set forth herein. 
 Severance Benefits Not in Connection With a Change in
Control:
 Without limiting the at-will nature of your employment with the Company, in the event that, outside of
the Protected Period (as defined in the Plan), Constellation terminates your employment without Cause (as defined below) or you resign your employment for Good Reason (as defined below), and subject to the Severance Conditions set forth below,
Constellation shall: (i) pay you in one lump sum a severance payment equivalent to (x) twelve (12) months of your then current base salary which amount shall, if your separation occurs prior to the
one-year anniversary of your start date, be multiplied by (y) a fraction the numerator of which is the number of days from the start date through and including the date employment ends and the denominator
of which is 365, less all applicable taxes and withholdings (the “Severance Pay”); and (ii) if you are eligible for and timely elect to continue receiving group medical and/or dental insurance under COBRA, until the earlier of
(x) the date that is twelve (12) months following your separation date, and (y) the date on which you obtain alternative coverage (as applicable, the “COBRA Contribution Period”), continue to pay the share of the premiums
for such coverage to the same extent it was paying such premiums on your behalf immediately prior to your separation date (though if, as a result of a change in legal requirements, the Company’s provision of payments for COBRA will violate the
nondiscrimination requirements of applicable law, this COBRA benefit will not apply) (collectively, the “Severance Benefits”). 
 The
Company’s obligation to provide you with the Severance Benefits is contingent upon your entering into a Severance and Release of Claims Agreement (the “Severance Agreement”) in a form to be provided by the Company (which will include,
at a minimum, a release of all releasable claims you may have and your agreement to non-disparagement, confidentiality, and cooperation obligations). The Severance Agreement must be signed by you, and any
applicable revocation period with respect thereto must have expired, by the 60th day following the end of your employment (or such shorter period as the Company may specify). Payment of the
Severance Pay will be made on the first regular payday after the Severance Agreement becomes effective; provided, however, that if the 60th day following your separation date occurs in the
calendar year following the year of your separation, then payment shall not be made before January 1 of such subsequent calendar year. 

 Cause: For purposes of this offer letter, “Cause” shall mean (i) a material breach of any
material term of any applicable offer letter or agreement between you and the Company, including the Employee Non-Competition, Non-Solicitation, Confidentiality and
Assignment Agreement referred to below, (ii) your plea of guilty or nolo contendere to, or your conviction of, a felony offense or a crime of dishonesty, (iii) your repeated unexplained or unjustified absences, refusals or failures to
carry out the lawful directions of the Board or the CEO, or (iv) your willful misconduct that results or is reasonably likely to result in material harm to the Company. 

Good Reason: For purposes of this offer letter, “Good Reason” shall mean (i) a material reduction of your base salary, (ii) a
material diminution of your authority, duties, or responsibilities, (iii) a requirement that your principal place of providing services to the Company change by more than 50 miles, other than in a direction that reduces your daily commuting
distance; or (iv) any material breach by the Company of a material provision of any agreement between you and the Company under which you provide services. Notwithstanding the occurrence of any of the foregoing events or circumstances, a
resignation shall not be deemed to constitute resignation for Good Reason unless (x) you give the Company a written notice of the purported Good Reason (no more than 90 days after the initial existence of such event or circumstance), (y) such
event or circumstance has not been fully corrected (and you have not been reasonably compensated for any losses or damages resulting therefrom) within 30 days following the Company’s receipt of such notice, and (z) if the Company does not
correct, you end your employment not more than 30 days following the period to correct in (y). 
 Payments Subject to
Section 409A: This offer letter, and any payments or other benefits under this offer letter, is intended to comply, to the extent applicable, with the provisions of Section 409A of the Internal Revenue Code of 1986, as
amended (“Section 409A”) and shall, to the extent practicable, be construed in accordance with such section and consistent with Exhibit A to this offer letter. 

Employment Eligibility: This offer of employment is contingent upon satisfactory reference checks, your signing Constellation’s standard form
of Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the “Non-Compete”), a copy of
which is enclosed, and I-9 Employment Verification. You will be required to submit documentation that establishes your identity and employment eligibility in accordance with the US Immigration and
Naturalization requirements within the first three days of your employment with the Company.
 Company Policies and Procedures: As an employee of the
Company, you will be required to comply with all Company policies and procedures. Violations of the Company’s policies may lead to immediate termination of your employment. Further, the Company’s premises, including all workspaces,
furniture, documents, and other tangible materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company at
any time. Company employees should have no expectation of privacy with regard to any Company premises, materials, resources, or information. 

Miscellaneous: You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering
into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter. If there are any agreements of any type that you are aware of which may impact or limit your ability to
perform your job at the Company, please let us know as soon as possible. 

 Please note that this offer letter is your formal offer of employment and supersedes any and all
prior or contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes under this letter will be governed by
Massachusetts law. 
 Please indicate your acceptance of this offer by signing in the appropriate space below and returning a signed copy of
this offer letter along with a signed copy of the Non-Compete to the attention of Brenda Sousa at Constellation Pharmaceuticals. We will discuss a formal start date and transition plan upon your acceptance of
this offer. 
 We are all very excited about the opportunity to work with you, Emma. Feel free to contact Brenda Sousa or me if you have any
questions or need more information. On behalf of all our team members, let me extend a sincere welcome. 
 Sincerely, 

 

	
	 /s/ Jigar Raythatha

	Jigar Raythatha
	President & CEO
	Constellation Pharmaceuticals, Inc.

 The foregoing correctly sets forth the terms of my at-will employment with
Constellation Pharmaceuticals, Inc. I am not relying on any representations other than those set forth above. 
  

					
	 /s/ Emma Reeva
	 	 10/15/17            
	 	
	Emma Reeve	 	Date	 	

 Enclosures: 
 ~Summary of
Constellation Benefits 
 ~Constellation’s Employee Non-Competition,
Non-Solicitation, Confidentiality and Assignment Agreement 

 Exhibit A 

Payments Subject to Section 409A 

The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided under this offer letter: 

 

	 	(a)	It is intended that each installment of the severance payments and benefits provided under this offer letter shall be treated as a separate “payment” for purposes of Section 409A of the Internal Revenue
Code and the guidance issued thereunder (“Section 409A”). Neither you nor Constellation shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required
by Section 409A. 

  

	 	(b)	If, as of the date of your “separation from service” from Constellation, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the severance payments
and benefits shall be made on the dates and terms set forth in this offer letter. 

  

	 	(c)	If, as of the date of your “separation from service” from Constellation, you are a “specified employee” (within the meaning of Section 409A), then: 

 

	 	(i)	Each installment of the severance payments and benefits due under this offer letter that is paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral
within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and shall be made on the dates and terms set forth in this offer letter; and

  

	 	(ii)	Each installment of the severance and benefits due under this offer letter that is not described in paragraph (i) above and that would, absent this subsection, be paid within the
six-month period following your “separation from service” from Constellation shall not be paid until the date that is six months and one day after such separation from service, (or, if earlier, upon
your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your separation
from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and
benefits if any to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
Section 1.409A-1(b)(iii) (relating to separation pay upon an involuntary “separation from service”. Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which separation from service occurs. 

	 	(d)	The determination of whether and when your separation from service from Constellation has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this paragraph (d), “Constellation” shall include all persons with whom Constellation would be considered a single employer under Sections 414(b) and 414(c)
of the Code. 

  

	 	(e)	All reimbursements and in-kind benefits provided under this offer letter shall be made or provided in accordance with the requirements of Section 409A to the extent that such
reimbursements or in-kind benefits are subject to Section 409A, including, where applicable the requirement that (i) any reimbursement is for expenses incurred during your lifetime (or during a
shorter period of time specified in this offer letter), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of
an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.

  

	 	(f)	Notwithstanding anything to the contrary in this offer letter, any payment or benefit under this offer letter or otherwise that may be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9)(v)(A) or (C) (relating to certain reimbursements and in-kind benefits) shall be paid or provided to you only to the extent that the expenses are
not incurred, or the benefits are not provided, beyond the last day of the second calendar year following the calendar year in which your “separation from service” occurs; and provided further that such expenses are reimbursed no later
than the last day of the third calendar year following the calendar year in which your “separation from service” occurs.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]